Funding to accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.

The Foundation Fighting Blindness (FFB) is a US-based 501(c)(3) charitable organisation that was founded as the National Retinitis Pigmentosa Foundation in 1971. Its mission is to support research that would lead to preventions, treatments, and vision restoration for the spectrum of degenerative retinal diseases, specifically macular degeneration, including age related macular degeneration, retinitis pigmentosa, Usher syndrome, Stargardt disease and Leber congenital amurosis (LCA).

The aim of the FFB Translational Research Acceleration Program (TRAP) is to accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.

The research priority areas are:

  • Novel Medical Therapies: approaches that use chemistry, biology, and bioengineering to formulate new therapies that mitigate inherited retinal degenerations and dry age-related macular degenerations
  • Genetic Technologies: the manipulation and modification of human gene expression to alter the biological properties of living cells/tissues with the goal of providing therapeutic solutions
  • Regenerative Medicine: the development, regeneration, and employment of human cells, tissues, and cellular/tissue-based products for the restoration of retinal function and vision

Research and technologies that fall outside of the scope of these areas may be considered with adequate preliminary data and justification.

Status Open
Funding body Medical
Maximum value $1,500,000
Reference ID S22257
Category Foundation Fighting Blindness (FFB)
Fund or call Fund

To search all the latest funds log in to ResearchConnect or contact us to subscribe

Log in
Subscribe